Journal of Genetic Medicine

Korean Society of Medical Genetics and Genomics (대한의학유전학회)
권호 표지
DOI QR코드

DOI QR Code

Genetic and clinical characteristics of Korean patients with neurofibromatosis type 2

  • Kim, Hye-ji (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Seo, Go Hun (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Kim, Yoon Myung (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Kim, Gu-Hwan (Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Seo, Eul-Ju (Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Ra, Young-Shin (Department of Neurosurgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Choi, Jin-Ho (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Yoo, Han-Wook (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Beom Hee (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
  • Received : 2017.05.29
  • Accepted : 2017.07.17
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Neurofibromatosis type 2 (NF2) is characterized by multiple tumors, including vestibular schwannoma (VS) and others affecting cranial and peripheral nerves. NF2 is caused by mutation of the NF2 gene. The mutation spectrum of NF2 has not been characterized in Korean patients. In the current study, the clinical and genetic characteristics of Korean NF2 patients were analyzed. Materials and Methods: Twenty-five unrelated Korean families were enrolled according to the Manchester criteria. Genetic analysis was performed by direct sequencing and multiplex ligation-dependent probe amplification methods using genomic DNA from peripheral lymphocytes or tumor tissues. Results: All patients had bilateral/unilateral VS and/or other cranial and peripheral nerve tumors. Two patients were familial cases and the other 24 patients were sporadic. Germline NF2 mutations were detected in peripheral lymphocytes from both familial cases, but only in 26.1% of the 23 sporadic families. Somatic mutations were also found in tumor tissues from two of the sporadic families. These somatic mutations were not found in peripheral lymphocytes. A total of 10 different mutations including 2 novel mutations were found in 40.0% of studied families. Five mutations (50.0%) were located in exon 6 of NF2, the FERM domain coding region. Conclusion: Family history was an important factor in identifying germline NF2 mutations. Further study is required to investigate whether exon 6 is a mutation hotspot in Korean NF2 patients and its correlation to phenotypic severity.

Keywords

References

  1. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16. https://doi.org/10.1186/1750-1172-4-16
  2. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005;26:93-7. https://doi.org/10.1097/00129492-200501000-00016
  3. Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: a common cause of classic disease in tumorprone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998;63:727-36.
  4. Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109-14. https://doi.org/10.1136/jmg.40.2.109
  5. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
  6. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575-8. https://doi.org/10.1001/archneur.1988.00520290115023
  7. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7. https://doi.org/10.1001/jama.1997.03550010065042
  8. Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet 2004;75:231-9. https://doi.org/10.1086/422700
  9. Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M, et al. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer 2005;42:384-91. https://doi.org/10.1002/gcc.20138
  10. Seong MW, Yeo IK, Cho SI, Park CK, Kim SK, Paek SH, et al. Molecular characterization of the NF2 gene in Korean patients with neurofibromatosis type 2: a report of four novel mutations. Korean J Lab Med 2010;30:190-4. https://doi.org/10.3343/kjlm.2010.30.2.190
  11. Yang HJ, Won YJ, Park KJ, Jung HW, Choi KS, Park JG. Germline mutations of the NF2 gene in Korean neurofibromatosis 2 patient. J Korean Cancer Assoc 1998;30:790-9.
  12. $GeneReviews^R$ [Internet]. Seattle, WA: University of Washington [cited 2017 Mar 8]. [http://www.ncbi.nlm.nih.gov/books/NBK1201/]
  13. Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 2007;28:1-12. https://doi.org/10.1002/humu.20393
  14. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, et al. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-8. https://doi.org/10.1007/s004390050255
  15. GenBank overview [Internet]. Bethesda, MD: NCBI [cited 2017 Mar 8]. [http://www.ncbi.nlm.nih.gov/genbank/]
  16. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998;77:228-33. https://doi.org/10.1002/(SICI)1096-8628(19980518)77:3<228::AID-AJMG8>3.0.CO;2-L
  17. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5. https://doi.org/10.1136/jmg.35.6.450
  18. Bourn D, Evans G, Mason S, Tekes S, Trueman L, Strachan T. Eleven novel mutations in the NF2 tumour suppressor gene. Hum Genet 1995;95:572-4.
  19. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature 2015;526:68-74. https://doi.org/10.1038/nature15393
  20. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003;21:577-81. https://doi.org/10.1002/humu.10212
  21. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285-91. https://doi.org/10.1038/nature19057
  22. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61. https://doi.org/10.1002/ajmg.1320520411
  23. Wallace AJ, Watson CJ, Oward E, Evans DG, Elles RG. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test 2004;8:368-80. https://doi.org/10.1089/gte.2004.8.368
  24. Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007;44:424-8. https://doi.org/10.1136/jmg.2006.047753
  25. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-63. https://doi.org/10.1136/jmg.40.6.459
  26. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett 2014;588:2743-52. https://doi.org/10.1016/j.febslet.2014.04.001
  27. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2012;158A:24-41. https://doi.org/10.1002/ajmg.a.34359
  28. Ruggieri M, Pratico AD, Evans DG. Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms. Semin Pediatr Neurol 2015;22:240-58. https://doi.org/10.1016/j.spen.2015.10.008
  29. ClinVar [Internet]. Bethesda, MD: NCBI [cited 2017 Mar 8]. [http://www.ncbi.nlm.nih.gov/clinvar/variation/201123]